Benefits
Sleep: no benefit over placebo in the controlled trial
The one placebo-controlled insomnia trial did not support this. Ninety-four adults took Wuling capsule and 92 took placebo for four weeks; both groups improved on the Pittsburgh Sleep Quality Index, but there was no significant difference between the groups, and clinical global impression and quality-of-life scores did not differ either. The authors concluded that none of the variables tested separated from placebo. Zylaria® is marketed for adults seeking gentle botanical sleep support alongside good sleep habits, but that is a marketing position and not a demonstrated effect.
Mood in one small pilot trial
Wu Ling Shen has a long history in Traditional Chinese Medicine for emotional balance and calm. The modern evidence is a single 12-week pilot trial in adults with epilepsy, a diagnosed condition managed by a doctor. Of 104 people randomised, 81 finished; the share rated as responding on depressive symptoms was 51.3% on Xylaria nigripes and 35.7% on placebo. The paper reports that gap as 0.15 with a 95% confidence interval of -0.06 to 0.37, an interval that includes zero, alongside P=0.002. Those two figures cannot both be right, and the interval is the more cautious reading. Nothing cited here measured stress or anxiety, and nothing was tested in healthy adults.
Next-day alertness has not been tested
This describes a product category rather than anything measured for Zylaria®. No cited study compared it with a sedative-hypnotic medicine or measured next-day alertness, and the safety notes on this page flag possible drowsiness, so freedom from daytime grogginess cannot be claimed.
Adjunct to sleep-hygiene routines
Zylaria® fits within a broader sleep-support strategy that includes consistent sleep timing, light exposure management, caffeine timing, and stress regulation. It is intended as a supportive ingredient rather than a stand-alone insomnia therapeutic.
Mechanism of action
GABA precursor and GABAergic signaling support
Xylaria nigripes preparations are enriched in free amino acids including GABA itself and related precursors. Preclinical work suggests GABAergic system modulation, potentially contributing to calming and sleep-promoting effects, although direct human neuropharmacology data remains limited.
HPA-axis and stress-response modulation
Traditional and emerging mechanistic work positions Xylaria nigripes within the family of adaptogen-like botanicals that may help modulate the hypothalamic-pituitary-adrenal axis during periods of perceived stress. This is a hypothesis: no study cited on this page measured cortisol or any other marker of HPA-axis activity.
Polysaccharide and small-molecule bioactives
Xylaria nigripes contains polysaccharides and small-molecule constituents that have been characterized in natural product chemistry studies. Several have been associated with neuroprotective or anti-inflammatory activity in preclinical assays, providing additional mechanistic rationale.
Clinical trials
Multicenter, randomized, double-blind, placebo-controlled trial of Xylaria nigripes (Wu Ling capsule) vs placebo in 104 adults with epilepsy and depressive symptoms over 12 weeks. Outcomes: Hamilton Depression Rating Scale, response rates. Published in Seizure.
104 adults with epilepsy and depressive symptoms randomised, 81 completed; 12-week intervention. A diagnosed disease population under medical care, not healthy adults.
The authors describe this as a pilot study. The primary endpoint, total effective rate for depressive symptoms, was 51.3% on Xylaria nigripes and 35.7% on placebo among the 81 people who completed. The paper gives that difference as 0.15 with a 95% confidence interval of -0.06 to 0.37, which includes zero, while also reporting P=0.002; the two statements are inconsistent and the confidence interval is the more cautious reading. No difference was found in seizure frequency or severity. Quality of life and the seizure worry subscale improved more on treatment. The product tested was generic Xylaria nigripes, not Zylaria®.
Multicenter, randomized, double-blind, placebo-controlled trial of Wuling capsule (Xylaria nigripes mycelial powder) at 3 g/day vs placebo in 186 Chinese adults with insomnia over 4 weeks, with 2-week follow-up. Outcomes: Pittsburgh Sleep Quality Index, clinical global impression, WHOQOL-BREF quality of life, safety. Published in Journal of Ethnopharmacology.
186 Chinese adults with insomnia; 4-week intervention plus 2-week follow-up.
Wuling capsule did not beat placebo. Both groups improved on the global Pittsburgh Sleep Quality Index against their own baseline, but there was no significant difference between the Wuling and placebo groups. Clinical global impression scores were similar to placebo at every week, and all four WHOQOL-BREF quality-of-life components improved in both groups with no difference between them. The authors concluded that none of the variables tested differed from placebo control. Adverse events were 10.10% on Wuling and 6.73% on placebo, not a significant difference. This is the most directly relevant placebo-controlled trial for Xylaria nigripes in sleep, and it is negative.